NICOLE MEZO: Open Payments
NPI 1861702441 · DENVER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,223 in 57 payments from 17 companies in 2025. Trend: 2023 $806 · 2024 $1,344 · 2025 $1,223
Food & beverage: $1,115Education: $108
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 15 | $241 |
| GlaxoSmithKline, LLC. | 10 | $181 |
| Novartis Pharmaceuticals Corporation | 5 | $101 |
| SANOFI-AVENTIS U.S. LLC | 1 | $100 |
| Regeneron Healthcare Solutions, Inc. | 3 | $82 |
| AstraZeneca Pharmaceuticals LP | 4 | $78 |
| Ionis Pharmaceuticals, Inc. | 2 | $77 |
| PFIZER INC. | 3 | $75 |
| CSL Behring | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
Products named: DUPIXENT, NUCALA, DAWNZERA, OCTAGAM IMMUNE GLOBULIN (HUMAN), TEZSPIRE, TRELEGY ELLIPTA, CUVITRU, Andembry.
Industry payments across CO — which companies pay providers there.
